Acute Kidney Injury Market Expansion Driven by Rising Diabetes Prevalence

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Estimated Market Size Of The Acute Kidney Injury Market In 2026, And How Will Its Value Evolve By 2030?

The acute kidney injury market size has experienced robust growth in recent years. Looking ahead, it is projected to expand from $5.72 billion in 2025 to $6.09 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 6.5%. This historical expansion was primarily driven by factors such as limited access to advanced renal care, an increasing prevalence of comorbidities like diabetes and hypertension, the development of hospital infrastructure, the adoption of conventional dialysis techniques, and growing awareness of AKI complications.

The acute kidney injury market is projected to experience substantial expansion over the upcoming years, with an anticipated growth to $7.78 billion by 2030, reflecting a compound annual growth rate (CAGR) of 6.3%. This growth during the forecast period can be attributed to advancements in renal replacement therapies, the development of novel nephroprotective drugs, the expansion of ambulatory surgical centers, an increasing utilization of biomarkers for early detection, and the integration of AI-based monitoring systems in renal care. Major trends expected in this period include a rising adoption of dialysis and drug therapies, the escalating global incidence of acute kidney injury, an intensified focus on early diagnosis and biomarker development, the broadening applications of urinary implants, and the integration of minimally invasive techniques in AKI management.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/acute-kidney-injury-global-market-report

What Primary Drivers Are Shaping The Acute Kidney Injury Market?

The rising incidence of diabetes is anticipated to drive the expansion of the acute kidney injury market in the coming period. Diabetes encompasses a range of metabolic conditions marked by elevated blood glucose levels, stemming from either insufficient insulin production by the body or inadequate cellular response to insulin. The growing occurrence of diabetes is fueled by elements like increasing obesity, unhealthy eating habits, inactive routines, an aging demographic, and improved detection and diagnostic capabilities. Acute kidney injury instigates metabolic and inflammatory alterations capable of affecting insulin resistance and glucose balance, thereby indicating an intricate relationship that could influence the advancement and treatment of diabetes. For example, data from March 2024, provided by the Office for Health Improvement & Disparities, a UK-based government department, showed that from March 2022 to March 2023, the proportion of individuals with type 1 diabetes receiving all eight recommended care processes saw a 22% increase, and for type 2 diabetes, this figure rose by 21%. Concurrently, the percentage reaching target HbA1c levels climbed to 37.9%, which represents the highest value ever recorded by the National Diabetes Audit (NDA). Consequently, the heightened prevalence of diabetes is propelling the expansion of the acute kidney injury market.

Which Segment Classifications Are Used In The Acute Kidney Injury Market Segment Analysis?

The acute kidney injury market covered in this report is segmented –

1) By Injury: Pre-Renal Kidney Injury, Post-Renal Kidney Injury, Intrinsic Kidney Injury

2) By Treatment Type: Renal Replacement Therapy (RRT), Pharmacological Management, Supportive and Conservative Management, Obstruction-Relief Interventions

3) By End User: Hospitals, Dialysis Centers, Specialty Clinics, Other End Users

Subsegments:

1) By Pre-Renal Kidney Injury: Hypovolemia, Heart Failure-Related Injury, Sepsis-Induced Injury, Renal Artery Stenosis, Hepatorenal Syndrome

2) By Post-Renal Kidney Injury: Ureteral Obstruction, Bladder Outlet Obstruction, Prostate Enlargement (Benign Prostatic Hyperplasia), Kidney Stones, Tumors Affecting Urinary Tract

3) By Intrinsic Kidney Injury: Acute Tubular Necrosis (ATN), Acute Interstitial Nephritis (AIN), Glomerulonephritis, Vasculitis, Rhabdomyolysis-Induced Injury

What Trends Are Affecting The Growth Of The Acute Kidney Injury Market?

Leading companies in the acute kidney injury (AKI) market are prioritizing the acquisition of regulatory authorizations to expand their product portfolios and introduce innovative treatment options. These regulatory approvals signify the official permission granted by regulatory bodies, such as the FDA or EMA, enabling a product to be sold and marketed after meeting established safety, efficacy, and quality benchmarks. For example, in December 2023, Mission Therapeutics Ltd., a UK-based biotechnology company, secured FDA approval to launch a Phase II clinical trial for its primary compound, MTX652, aimed at acute kidney injury (AKI) in patients at elevated risk subsequent to cardiac surgery. This compound is formulated to target essential pathways involved in kidney damage and repair, seeking to diminish inflammation, avert further renal harm, and encourage recovery. A key distinction of this trial is its dedication to exploiting novel therapeutic mechanisms to address the core molecular causes of AKI, which could present more efficacious treatment alternatives compared to existing interventions. The Phase II trial will evaluate MTX652’s safety, efficacy, and pharmacokinetics, yielding critical data that could underpin wider clinical uptake and potential approval.

Which Firms Are Contributing To The Acute Kidney Injury Market Ecosystem?

Major companies operating in the acute kidney injury market are Fresenius Medical Care AG & Co. KGaA, Baxter International Inc., B. Braun Melsungen AG, Nipro Corporation, Nikkiso Co. Ltd., Asahi Kasei Medical Co. Ltd., Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Quark Pharmaceuticals Inc., Kringle Pharma Inc., Aptabio Therapeutics Inc., AM-Pharma B.V., Arch Biopartners Inc., Guard Therapeutics International AB

Get The Full Acute Kidney Injury Market Report:

https://www.thebusinessresearchcompany.com/report/acute-kidney-injury-global-market-report

Which Region Is The Leading Market For The Acute Kidney Injury Market?

North America was the largest region in the acute kidney injury market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute kidney injury market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Acute Kidney Injury Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/acute-kidney-injury-global-market-report

Browse Through More Reports Similar to the Global Acute Kidney Injury Market 2026, By The Business Research Company

Rare Kidney Diseases Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-kidney-diseases-global-market-report

Kidney Dialysis Market Report 2026

https://www.thebusinessresearchcompany.com/report/kidney-dialysis-global-market-report

Acute Spinal Cord Injury Market Report 2026

https://www.thebusinessresearchcompany.com/report/acute-spinal-cord-injury-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795